Confronto
Carbetocin vs. DSIP
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
37025-55-1
62568-57-4
Peso molecolare
nessun dato
848.81 g/mol
Emivita
0.67 h
0.1 h
Sequenza
nessun dato
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluMeccanismo d'azione
Carbetocin
Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
1
4
di cui sull'uomo
1
1
Effetti registrati
2
3
Contraddizioni aperte
0
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Carbetocin and DSIP?
- Carbetocin is classified as "Ricerca (altro)", while DSIP is classified as "Ricerca (altro)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Carbetocin or DSIP?
- The highest available evidence level is "RCT sull'uomo" for Carbetocin and "Studio sull'uomo" for DSIP. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Carbetocin and DSIP in Germany and the United States?
- Germania: Carbetocin — Su prescrizione, DSIP — Non approvato. Stati Uniti: Carbetocin — Non approvato, DSIP — Non approvato. These are factual summaries with source and review date on the individual pages.